噬菌体T4载体经鼻接种尼帕病毒G或F蛋白疫苗实现完全保护
尼帕病毒致死率约40%至70%,目前无获批疫苗或疗法。本研究以噬菌体T4为载体平台,开发靶向尼帕病毒附着糖蛋白G或融合糖蛋白F的新型疫苗。小鼠经鼻免疫可激发体液免疫、细胞免疫及黏膜免疫应答;叙利亚仓鼠经鼻免疫T4-G、T4-F或两者1:1混合物后,对致死性尼帕病毒攻击实现完全保护。
要点
- 噬菌体T4偶联尼帕病毒G或F蛋白经鼻免疫可诱导小鼠体液、细胞及黏膜免疫。
- 叙利亚仓鼠经鼻免疫T4-G、T4-F或1:1混合物后对致死性尼帕病毒攻击完全保护。
- 噬菌体T4载体安全且模块化通用,有望用于尼帕病毒及其他病毒疫苗开发。
核心结论
- 经鼻接种噬菌体T4偶联尼帕病毒G或F蛋白疫苗可在叙利亚仓鼠中实现对致死性尼帕病毒攻击的完全保护。
研究设计与样本
- 研究以噬菌体T4为载体平台开发靶向尼帕病毒G或F蛋白的新型疫苗,并在小鼠中比较经鼻免疫与肌内注射的免疫效果,在叙利亚仓鼠中进行致死性攻击保护实验。
主要发现
- 小鼠经鼻免疫T4-G或T4-F可激发体液免疫、细胞免疫及良好的黏膜免疫应答。
- 叙利亚仓鼠经鼻免疫T4-G、T4-F或两者1:1混合物后,对致死性尼帕病毒攻击均实现完全保护。
临床怎么用
- 提示噬菌体T4载体经鼻疫苗可作为尼帕病毒疫苗研发的候选策略,其安全性和模块化通用性支持进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nipah virus (NiV) is a highly lethal zoonotic pathogen, causing disease that can spread between animals and people with a mortality rate about 40% to 70%. No commercially approved vaccines or therapeutics are available. In this study, novel NiV vaccines targeting the attachment glycoprotein (G) or fusion glycoprotein (F) of NiV were developed utilizing bacteriophage T4 as a carrier platform. The immune effects induced in mice by intranasal immunization (i.n.) and intramuscular injection (i.m.) show that i.n. immunization with bacteriophage T4 coupled with Nipah virus G or F protein can not only stimulate humoral immunity and cellular immunity, but also induce excellent mucosal immune responses. Complete protection against lethal NiV challenge was achieved in Syrian hamsters after intranasal immunization with either T4-G, T4-F, or the mixture of T4-G and T4-F (1:1). Due to its safety and modular versatility, the bacteriophage T4 carrier system presents a promising strategy for developing vaccines against NiV and other viruses.
引用
- Chen M, Zhang X, Yao Y, et al. Complete protection against lethal Nipah virus challenge by intranasal vaccination with bacteriophage T4 coupled with Nipah virus G or F protein. Vaccine. 2026. PMID: 42140090. doi:10.1016/j.vaccine.2026.128727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。